Installing a "Live" Switch for the Heart: Chinese Scientists Achieve Neural Regulation of Heartbeat in a Petri Dish for the First Time
Release time:
2026-05-22
The heart’s tireless beating is made possible by a rice-sized "natural pacemaker" in the right atrium—the sinoatrial node. Acting like an indefatigable "commander," it continuously sends out electrical signals that direct the atria and ventricles to contract in harmony, pumping blood throughout the body. If this "commander" fails, the heartbeat slows or even stops, which can be life-threatening.

However, studying this "human heart switch" has been extremely challenging: the sinoatrial node is small, deeply embedded, and human samples are difficult to obtain. Animal models, such as mice, fail to accurately replicate the intricate regulation of human heart rhythm and the nervous system.
Recently, a research team led by Dr. Zeng An at the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, in collaboration with other researchers, published a breakthrough in the international journal Cell Stem Cell. Using human pluripotent stem cells, they successfully constructed a human "biological pacemaker"—a sinoatrial node organoid—in a petri dish. For the first time, they connected it to a cardiac plexus organoid, achieving real-time neural regulation of the heartbeat.
Acting like "directors," the team mimicked key developmental signals and systematically guided stem cells to differentiate into three-dimensional sinoatrial node organoids. These sesame-sized organoids not only generated stable, spontaneous heartbeats but also exhibited the electrophysiological characteristics of a real sinoatrial node. When the researchers "connected" the organoid to an atrial-like organoid, electrical signals were transmitted from the sinoatrial node to the atrial tissue, faithfully replicating the entire "pacemaker-conduction" process seen in the body.
Even more critically, the scientists also "linked" the sinoatrial node organoid with a cardiac plexus organoid. As a result, neural signals could accelerate or decelerate the organoid's beating frequency—just as they do in the body. This marks the first time a complete "pacemaker + neural regulation" system has been reconstructed outside the human body.
"This provides an unprecedented living model for studying cardiac arrhythmias," said Dr. Zeng An. In the past, research relied on animal experiments, making it difficult to detect potential arrhythmic side effects of drugs in humans. Now, with a patient’s own stem cells, researchers can create a "personalized heart model" to test drug toxicity, screen treatment options, and even lay the groundwork for future battery-free, non-rejectable "biological pacemakers."
Industry experts believe this achievement represents a critical step forward for China in the fields of cardiac organoids and regenerative medicine, bringing new hope to hundreds of millions of arrhythmia patients worldwide.
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.